WHO ICTRP trial
An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy…
NL-OMON30663 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON30663 |
|---|---|
| Public title | An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia |
| Scientific title | An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia - Paliperidone ER flexible dosing in schizophrenia |
| Primary sponsor | Johnson & Johnson Pharmaceutical |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | The Netherlands |
| Conditions | schizophrenia;10039628;schizophrenia |
| Interventions | Existing oral antipsychotics will be stopped immediately or tapered off at the moment treatment with paliperidone ER starts. The recommended starting dose is 6 mg/day. Treatment starts after baseline assessments. Based on response and… |
| Registration date | Jul 15, 2008 |
| Target size | 48 |
| Secondary IDs | 2006-004265-34;NL15822.028.07;nog niet bekend |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: